Long-term outcome of prenatal treatment of congenital adrenal hyperplasia

Endocrine Development

Volumn 13, Issue , 2008, Pages 82-98

  Lajic, S ^a,b   Nordenstrom A ^a   Hirvikoski, T ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; STEROID 21 MONOOXYGENASE;

ANIMAL; ANIMAL MODEL; BIOLOGICAL MODEL; CENTRAL NERVOUS SYSTEM; CHEMICALLY INDUCED DISORDER; CONGENITAL ADRENAL HYPERPLASIA; DRUG EFFECT; EVALUATION; FEMALE; FETUS DISEASE; GENETICS; GROWTH, DEVELOPMENT AND AGING; HORMONE SUBSTITUTION; HUMAN; PREGNANCY; PRENATAL DEVELOPMENT; PRENATAL DIAGNOSIS; PRENATAL EXPOSURE; PSYCHOLOGICAL ASPECT; REVIEW; TIME; TREATMENT OUTCOME;

ADRENAL HYPERPLASIA, CONGENITAL; ANIMALS; CENTRAL NERVOUS SYSTEM; FEMALE; FETAL DISEASES; GLUCOCORTICOIDS; HORMONE REPLACEMENT THERAPY; HUMANS; MODELS, ANIMAL; MODELS, BIOLOGICAL; PREGNANCY; PRENATAL DIAGNOSIS; PRENATAL EXPOSURE DELAYED EFFECTS; STEROID 21-HYDROXYLASE; TIME FACTORS; TREATMENT OUTCOME;

EID: 48949092019     PISSN: 14217082     EISSN: 16622979     Source Type: Book Series    
DOI: 10.1159/000134827     Document Type: Review

References (79)

1. Therrell BL Jr, Berenbaum SA, Manter-Kapanke V, Simmank J, Korman K, Prentice L, Gonzalez J, Gunn S: Results of screening 1.9 million texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics 1998;101:583-590.
2. Auchus RJ: The backdoor pathway to dihydrotestosterone. Trends Endocrinol Metab 2004;15:432-438.
3. Hanley NA, Arlt W: The human fetal adrenal cortex and the window of sexual differentiation. Trends Endocrinol Metab 2006;17:391-397.
4. White PC, Speiser PW: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000;21:245-291.
5. Thilen A, Nordenstrom A, Hagenfeldt L, von Dobeln U, Guthenberg C, Larsson A: Benefits of neonatal screening for congenital adrenal hyperplasia (21-hydroxylase deficiency) in sweden. Pediatrics 1998;101:694.
6. Nordenstrom A, Ahmed S, Jones J, Coleman M, Price DA, Clayton PE, Hall CM: Female preponderance in congenital adrenal hyperplasia due to cyp21 deficiency in england: Implications for neonatal screening. Horm Res 2005;63:22-28.
7. Brosnan PG, Brosnan CA, Kemp SF, Domek DB, Jelley DH, Blackett PR, Riley WJ: Effect of newborn screening for congenital adrenal hyperplasia. Arch Pediatr Adolesc Med 1999;153:1272-1278.
8. Tusie-Luna M-T, Traktman P, White PC: Determination of functional effects of mutations in the steroid 21-hydroxylase gene (cyp21) using recombinant vaccinia virus. J Biol Chem 1990;265:20916-20922.
9. Lajic S, Robins T, Krone N, Schwarz HP, Wedell A: Cyp21 mutations in simple virilizing congenital adrenal hyperplasia. J Mol Med 2001;79:581-586.
10. Prader A: [genital findings in the female pseudohermaphroditism of the congenital adrenogenital syndrome; morphology, frequency, development and heredity of the different genital forms.]. [german]. Helv Paediatr Acta 1954;9:231-248.
11. White PC, Grossberger D, Onufer BJ, Chaplin DD, New MI, Dupont B, Strominger JL: Two genes encoding steroid 21-hydroxylase are located near the genes encoding the fourth component of complement in man. Proc Natl Acad Sci USA 1985;82:1089-1093.
12. Morel Y, Murena M, Nicolino M, Carel JC, David M, Forest MG: Correlation between genetic lesions of the cyp21b gene and the clinical forms of congenital adrenal hyperplasia (cah) due to 21-hydroxylase deficiency: Report of a large study of 355 cah chromosomes. Horm Res 1992;37:13.
13. Wedell A: An update on the molecular genetics of congenital adrenal hyperplasia: Diagnostic and therapeutic aspects. J Pediatr Endocrinol Metab 1998;11:581-589.
14. White PC, Tusie-Luna MT, New MI, Speiser PW: Mutations in steroid 21-hydroxylase (cyp21). Hum Mutat 1994;3:373-378.
15. Lajic S, Clauin S, Robins T, Vexiau P, Blanche H, Bellanne-Chantelot C, Wedell A: Novel mutations in cyp21 detected in individuals with hyperandrogenism. J Clin Endocrinol Metab 2002;87:2824-2829.
16. Robins T, Bellanne-Chantelot C, Barbaro M, Cabrol S, Wedell A, Lajic S: Characterization of novel missense mutations in cyp21 causing congenital adrenal hyperplasia. J Mol Med 2007;85:243-251.
17. Barbaro M, Lajic S, Baldazzi L, Balsamo A, Pirazzoli P, Cicognani A, Wedell A, Cacciari E: Functional analysis of two recurrent amino acid substitutions in the cyp21 gene from italian patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2004;89:2402-2407.
18. Wedell A, Thilén A, Ritzén EM, Stengler B, Luthman H: Mutational spectrum of the steroid 21-hydroxylase gene in sweden: Implications for genetic diagnosis and association with disease manifestation. J Clin Endocrinol Metab 1994;78:1145-1152.
19. Mao R, Nelson L, Kates R, Miller CE, Donaldson DL, Tang W, Ward K: Prenatal diagnosis of 21-hydroxylase deficiency caused by gene conversion and rearrangements: Pitfalls and molecular diagnostic solutions. Prenat Diagn 2002;22:1171-1176.
20. David M, Forest MG: Prenatal treatment of congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency. J Pediatr 1984;105:799-803.
21. Goto M, Piper Hanley K, Marcos J, Wood PJ, Wright S, Postle AD, Cameron IT, Mason JI, Wilson DI, Hanley NA: In humans, early cortisol biosynthesis provides a mechanism to safeguard female sexual development. J Clin Invest 2006;116:953-960.
22. Bischoff FZ, Lewis DE, Simpson JL: Cell-free fetal DNA in maternal blood: Kinetics, source and structure. Hum Reprod Update 2005;11:59-67.
23. Rijnders RJ, van der Schoot CE, Bossers B, de Vroede MA, Christiaens GC: Fetal sex determination from maternal plasma in pregnancies at risk for congenital adrenal hyperplasia. Obstet Gynecol 2001;98:374-378.
24. Morel Y, Tardy V, Costa JM, Forest MG, David M: [21 hydroxylase deficiency: New strategies emerging from molecular studies]. Ann Endocrinol (Paris) 2003;64:456-470.
25. Forest MG, David M, Morel Y: Prenatal diagnosis and treatment of 21-hydroxylase deficiency. J Steroid Biochem Mol Biol 1993;45:75-82.
26. Forest MG, Dörr HG: Prenatal therapy in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: Retrospective follow-up study of 253 treated pregnancies in 215 families. Endocrinologist 2003;13:252-259.
27. Mercado AB, Wilson RC, Cheng KC, Wei J-Q, New MI: Prenatal treatment and diagnosis of congenital adrenal hyperplasia owing to steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab 1995;80:2014-2020.
28. Carlson AD, Obeid JS, Kannelopoulou N, Wilson RC, New MI: Congenital adrenal hyperplasia: Update on prenatal diagnosis and treatment. J Steroid Biochem Mol Biol 1999;69:19-29.
29. New MI, Carlson A, Obeid J, Marshall I, Cabrera MS, Goseco A, Lin-Su K, Putnam AS, Wei JQ, Wilson RC: Prenatal diagnosis for congenital adrenal hyperplasia in 532 pregnancies. J Clin Endocrinol Metab 2001;86:5651-5657.
30. Lajic S, Wedell A, Bui TH, Ritzen EM, Holst M: Long-term somatic follow-up of prenatally treated children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 1998;83:3872-3880.
31. Berenbaum SA, Duck SC, Bryk K: Behavioral effects of prenatal versus postnatal androgen excess in children with 21-hydroxylase-deficient congenital adrenal hyperplasia. J Clin Endocrinol Metab 2000;85:727-733.
32. Servin A, Nordenstrom A, Larsson A, Bohlin G: Prenatal androgens and gender-typed behavior: A study of girls with mild and severe forms of congenital adrenal hyperplasia. Dev Psychol 2003;39:440-450.
33. Hall CM, Jones JA, Meyer-Bahlburg HF, Dolezal C, Coleman M, Foster P, Price DA, Clayton PE: Behavioral and physical masculinization are related to genotype in girls with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2004;89:419-424.
34. Berenbaum SA, Bailey JM: Effects on gender identity of prenatal androgens and genital appearance: Evidence from girls with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2003;88:1102-1106.
35. Meyer-Bahlburg HF, Dolezal C, Baker SW, Carlson AD, Obeid JS, New MI: Prenatal androgenization affects gender-related behavior but not gender identity in 5-12-year-old girls with congenital adrenal hyperplasia. Arch Sex Behav 2004;33:97-104.
36. Barker DJ, Eriksson JG, Forsen T, Osmond C: Fetal origins of adult disease: Strength of effects and biological basis. Int J Epidemiol 2002;31:1235-1239.
37. Seckl JR, Holmes MC: Mechanisms of disease: Glucocorticoids, their placental metabolism and fetal 'programming' of adult pathophysiology. Nat Clin Pract Endocrinol Metab 2007;3:479-488.
38. Seckl JR, Miller WL: How safe is long-term prenatal glucocorticoid treatment? JAMA 1997;277:1077-1079.
39. Miller WL: Dexamethasone treatment of congenital adrenal hyperplasia in utero: An experimental therapy of unproven safety. J Urol 1999;162:537-540.
40. Seckl JR: Prenatal glucocorticoids and long-term programming. Eur J Endocrinol 2004;151(suppl 3):U49-U62.
41. Dodic M, Tersteeg M, Jefferies A, Wintour EM, Moritz K: Prolonged low-dose dexamethasone treatment, in early gestation, does not alter blood pressure or renal function in adult sheep. J Endocrinol 2003;179:275-280.
42. Sloboda DM, Moss TJ, Gurrin LC, Newnham JP, Challis JR: The effect of prenatal betamethasone administration on postnatal ovine hypothalamic-pituitary- adrenal function. J Endocrinol 2002;172:71-81.
43. Sloboda DM, Moss TJ, Li S, Doherty D, Nitsos I, Challis JR, Newnham JP: Prenatal betamethasone exposure results in pituitary-adrenal hyporesponsiveness in adult sheep. Am J Physiol Endocrinol Metab 2007;292:E61-E70.
44. Uno H, Eisele S, Sakai A, Shelton S, Baker E, DeJesus O, Holden J: Neurotoxicity of glucocorticoids in the primate brain. Horm Behav 1994;28:336-348.
45. de Vries A, Holmes MC, Heijnis A, Seier JV, Heerden J, Louw J, Wolfe-Coote S, Meaney MJ, Levitt NS, Seckl JR: Prenatal dexamethasone exposure induces changes in nonhuman primate offspring cardiometabolic and hypothalamic-pituitary-adrenal axis function. J Clin Invest 2007;117:1058-1067.
46. Dalziel SR, Walker NK, Parag V, Mantell C, Rea HH, Rodgers A, Harding JE: Cardiovascular risk factors after antenatal exposure to betamethasone: 30-year follow-up of a randomised controlled trial. Lancet 2005;365:1856-1862.
47. Anderson V, Northam E, Hendy J, Wrennall J: Cerebral development. Developmental neuropsychology: A clinical approach. Hove, Psychology Press, 2001, pp 39-68.
48. Bayer SA, Altman J, Russo RJ, Zhang X: Timetables of neurogenesis in the human brain based on experimentally determined patterns in the rat. Neurotoxicology 1993;14:83-144.
49. Matthews SG: Antenatal glucocorticoids and the developing brain: Mechanisms of action. Semin Neonatol 2001;6:309-317.
50. McEwen B, Chao H, Spencer R, Brinton R, Macisaac L, Harrelson A: Corticosteroid receptors in brain: Relationship of receptors to effects in stress and aging. Ann NY Acad Sci 1987;512:394-401.
51. Patel PD, Lopez JF, Lyons DM, Burke S, Wallace M, Schatzberg AF: Glucocorticoid and mineralocorticoid receptor mrna expression in squirrel monkey brain. J Psychiatr Res 2000;34:383-392.
52. Sanchez MM, Young LJ, Plotsky PM, Insel TR: Distribution of corticosteroid receptors in the rhesus brain: Relative absence of glucocorticoid receptors in the hippocampal formation. J Neurosci 2000;20:4657-4668.
53. Charmandari E, Kino T, Souvatzoglou E, Chrousos GP: Pediatric stress: Hormonal mediators and human development. Horm Res 2003;59:161-179.
54. Kapoor A, Petropoulos S, Matthews SG: Fetal programming of hypothalamic-pituitary-adrenal (hpa) axis function and behavior by synthetic glucocorticoids. Brain Res Rev 2008;57:586-595.
55. Belanoff JK, Gross K, Yager A, Schatzberg AF: Corticosteroids and cognition. J Psychiatr Res 2001;35:127-145.
56. Bender BG, Lerner JA, Poland JE: Association between corticosteroids and psychologic change in hospitalized asthmatic children. Ann Allergy 1991;66:414-419.
57. Nass R, Heier L, Moshang T, Oberfield S, George A, New MI, Speiser PW: Magnetic resonance imaging in the congenital adrenal hyperplasia population: Increased frequency of white-matter abnormalities and temporal lobe atrophy. J Child Neurol 1997;12:181-186.
58. Dalziel SR, Lim VK, Lambert A, McCarthy D, Parag V, Rodgers A, Harding JE: Antenatal exposure to betamethasone: Psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ 2005;331:665.
59. French NP, Hagan R, Evans SF, Mullan A, Newnham JP: Repeated antenatal corticosteroids: Effects on cerebral palsy and childhood behavior. Am J Obstet Gynecol 2004;190:588-595.
60. Wapner RJ, Sorokin Y, Mele L, Johnson F, Dudley DJ, Spong CY, Peaceman AM, Leveno KJ, Malone F, Caritis SN, Mercer B, Harper M, Rouse DJ, Thorp JM, Ramin S, Carpenter MW, Gabbe SG: Long-term outcomes after repeat doses of antenatal corticosteroids. N Engl J Med 2007;357:1190-1198.
61. Yeh TF, Lin YJ, Lin HC, Huang CC, Hsieh WS, Lin CH, Tsai CH: Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 2004;350:1304-1313.
62. Yeh TF, Lin YJ, Huang CC, Chen YJ, Lin CH, Lin HC, Hsieh WS, Lien YJ: Early dexamethasone therapy in preterm infants: A follow-up study. Pediatrics 1998;101:E7.
63. Baud O, Sola A: Corticosteroids in perinatal medicine: How to improve outcomes without affecting the developing brain? Semin Fetal Neonatal Med 2007;12:273-279.
64. Celsi G, Kistner A, Aizman R, Eklof AC, Ceccatelli S, de Santiago A, Jacobson SH: Prenatal dexamethasone causes oligonephronia, sodium retention, and higher blood pressure in the offspring. Pediatr Res 1998;44:317-322.
65. Emgard M, Paradisi M, Pirondi S, Fernandez M, Giardino L, Calza L: Prenatal glucocorticoid exposure affects learning and vulnerability of cholinergic neurons. Neurobiol Aging 2007;28:112-121.
66. Slotkin TA, Kreider ML, Tate CA, Seidler FJ: Critical prenatal and postnatal periods for persistent effects of dexamethasone on serotonergic and dopaminergic systems. Neuropsychopharmacology 2006;31:904-911.
67. McArthur S, McHale E, Gillies GE: The size and distribution of midbrain dopaminergic populations are permanently altered by perinatal glucocorticoid exposure in a sex- region- and time-specific manner. Neuropsychopharmacology 2007;32:1462-1476.
68. Welberg LA, Seckl JR, Holmes MC: Prenatal glucocorticoid programming of brain corticosteroid receptors and corticotrophin-releasing hormone: Possible implications for behaviour. Neuroscience 2001;104:71-79.
69. Uno H, Lohmiller L, Thieme C, Kemnitz JW, Engle MJ, Roecker EB, Farrell PM: Brain damage induced by prenatal exposure to dexamethasone in fetal rhesus macaques. I. Hippocampus. Brain Res Dev Brain Res 1990;53:157-167.
70. Trautman PD, Meyer-Bahlburg HF, Postelnek J, New MI: Effects of early prenatal dexamethasone on the cognitive and behavioral development of young children: Results of a pilot study. Psychoneuroendocrinology 1995;20:439-449.
71. Meyer-Bahlburg HF, Dolezal C, Baker SW, Carlson AD, Obeid JS, New MI: Cognitive and motor development of children with and without congenital adrenal hyperplasia after early-prenatal dexamethasone. J Clin Endocrinol Metab 2004;89:610-614.
72. Hirvikoski T, Nordenstrom A, Lindholm T, Lindblad F, Ritzen EM, Wedell A, Lajic S: Cognitive functions in children at risk for congenital adrenal hyperplasia treated prenatally with dexamethasone. J Clin Endocrinol Metab 2007;92:542-548.
73. Achenbach TM, McConaughy SH, Howell CT: Child/ adolescent behavioral and emotional problems: Implications of cross-informant correlations for situational specificity. Psychol Bull 1987;101:213-232.
74. Baddeley A: Working memory. Oxford, Clarendon Press, 1986.
75. Arnsten AF: Fundamentals of attention-deficit/ hyperactivity disorder: Circuits and pathways. J Clin Psychiatry 2006;67(suppl 8):7-12.
76. Liu L, Li A, Matthews SG: Maternal glucocorticoid treatment programs hpa regulation in adult offspring: Sex-specific effects. Am J Physiol Endocrinol Metab 2001;280:E729-E739.
77. Banjanin S, Kapoor A, Matthews SG: Prenatal glucocorticoid exposure alters hypothalamic-pituitary-adrenal function and blood pressure in mature male guinea pigs. J Physiol 2004;558:305-318.
78. Meaney MJ, Szyf M, Seckl JR: Epigenetic mechanisms of perinatal programming of hypothalamic-pituitary-adrenal function and health. Trends Mol Med 2007;13:269-277.
79. Drake AJ, Walker BR, Seckl JR: Intergenerational consequences of fetal programming by in utero exposure to glucocorticoids in rats. Am J Physiol Regul Integr Comp Physiol 2005;288:R34-R38.